First Type 1 Diabetes Patient Enrolled in Rise Therapeutics’ Latest Clinical Trial

UF startup Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, announced it has enrolled its first patient in its R-5280 placebo-controlled, blinded, Phase 1b type 1 diabetes clinical trial.

Gary Fanger, president and chief executive officer of Rise Therapeutics, stated, “With our third drug now in clinical development, we have the opportunity with R-5280 to control another devastating disease using an oral immunotherapy approach.”

Type 1 diabetes is a chronic autoimmune condition in which the pancreas produces little to no insulin. Without enough insulin, blood sugar levels can become dangerously high. Type 1 diabetes typically develops in childhood or adolescence and patients require lifelong insulin therapy to manage their blood sugar levels and prevent complications. Approximately 1.6 million people in the United States are affected by type 1 diabetes, and around 40,000 people receive a new diagnosis of type 1 diabetes in the U.S. each year.

Read more about First Type 1 Diabetes Patient Enrolled in Rise Therapeutics’ Latest Clinical Trial.